Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worldwide. A causal link between mRNA vaccines and GBS has not been previously evaluated. We analyzed a cohort of 3,890,250 Hispanic/Latinx recipients of the BNT162b2 mRNA vaccine (613,780 of whom had already received both doses) for incident GBS occurring within 30 days from vaccine administration. Seven cases of GBS were detected among first-dose recipients, for an observed incidence of 0.18/100,000 administered doses during the prespecified timeframe of 30 days. No cases were reported after second-dose administration. Our data suggest that, among recipients of the BNT162b2 mRNA vaccine, GBS may occur at the expected community-based rate; however, this should be taken with caution as the current incidence of GBS among the unvaccinated population against COVID-19 is still undetermined. We hope that this preliminary data will increase the public perception of safety toward mRNA-based vaccines and reduce vaccine hesitancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“Within months after the first case of SARS-CoV-2 infection was detected, two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) [1] and mRNA-1273 (Moderna) [2] have demonstrated to reduce COVID-19 incidence and severity effectively [3].”
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387 · cited 1×
“GBS may occur spontaneously after bacterial or viral infections, and it has been historically linked to several vaccines, but epidemiological studies have not found a direct association between current vaccines and GBS [10,11].”
Gee, J., Marquez, P., Su, J., Calvert, G. M., Liu, R., Myers, T., Nair, N., Martin, S., Clark, T., Markowitz, L., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7008e3 · Cited by 395 · cited 1×
“Within months after the first case of SARS-CoV-2 infection was detected, two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) [1] and mRNA-1273 (Moderna) [2] have demonstrated to reduce COVID-19 incidence and severity effectively [3].”
Bell's palsy and SARS-CoV-2 vaccines
Ozonoff, A., Nanishi, E., & Levy, O. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00076-1 · Cited by 158 · cited 1×
“Hypothetically, vaccines may lead to the loss of selftolerance and autoimmune disease and cause neural tissue damage, although, with current vaccines, the association is neither supported by empirical nor epidemiological [7,8].”
Greene, S. K., Rett, M. D., Vellozzi, C., Li, L., Kulldorff, M., Marcy, S. M., Daley, M. F., Belongia, E. A., Baxter, R., Fireman, B. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067185 · Cited by 59
Cited by
New‐onset autoimmune phenomena post‐COVID‐19 vaccination
Chen, Y., Xu, Z., Wang, P., Li, X., Shuai, Z., Ye, D., & Pan, H. (2022) · Immunology · doi:10.1111/imm.13443 · Cited by 502
Li, X., Raventós, B., Roel, E., Pistillo, A., Martinez-Hernandez, E., Delmestri, A., Reyes, C., Strauss, V., Prieto-Alhambra, D., Burn, E., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068373 · Cited by 118
Walker, J. L., Schultze, A., Tazare, J., Tamborska, A., Singh, B., Donegan, K., Stowe, J., Morton, C. E., Hulme, W. J., Curtis, H. J., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.010 · Cited by 30
Atzenhoffer, M., Auffret, M., Pegat, A., Masmoudi, K., Khouri, C., Bertin, B., & Vial, T. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01164-4 · Cited by 20
Metadata
- Authors
- García-Grimshaw, M., Michel-Chávez, A., Vera-Zertuche, J. M., Galnares-Olalde, J. A., Hernández-Vanegas, L. E., Figueroa-Cucurachi, M., Paredes-Ceballos, O., Reyes-Terán, G., Carbajal-Sandoval, G., Ceballos-Liceaga, S. E., Arauz, A., & Valdés-Ferrer, S. I.
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 230
- Pages
- 108818
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W3191936386
- Cited by
- 74
- References
- 7
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. https://app.cochat.ai/papers/10.1016/j.clim.2021.108818
- The paper
- García-Grimshaw, M., Michel-Chávez, A., Vera-Zertuche, J. M., Galnares-Olalde, J. A., Hernández-Vanegas, L. E., Figueroa-Cucurachi, M., Paredes-Ceballos, O., Reyes-Terán, G., Carbajal-Sandoval, G., Ceballos-Liceaga, S. E., Arauz, A., & Valdés-Ferrer, S. I. (2021). Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clinical Immunology. https://doi.org/10.1016/j.clim.2021.108818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.